fashion -WSS

fashion

author：fashion 2025-10-01 14:15:27 - browse：9818

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Sanders wants to replace patents with prizes for drug inventions

knowledge

WSS

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Congress likely to miss an opportunity to fix drug shortages issue

Can CDC director Mandy Cohen drive consensus in Washington?

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Can CDC director Mandy Cohen drive consensus in Washington?

Extensive review finds private equity owners jack up cost of care

leisure time

fashion

leisure time

Walensky prepares to leave CDC — and Congress — behind

Argenx drug significantly slows progression of nerve disorder

Anesthesiologist group: stop taking Ozempic before surgery

There’s a way to spot data fakery. All journals should be using it

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Blood tests recalled over risk of missed heart attack diagnosis

Continuity nursing helped my family in our darkest PICU moments

Telehealth startups are trying to fill the menopause care vacuum

How one medical school became remarkably diverse

Stanford president’s abrupt resignation sparks debate

knowledge

'CMA Fest' 2023: How to watch, who is performing and more

Grail faces three suits alleging harassment, retaliation

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

After a decade, new Gardasil ad campaign gets it (mostly) right

Hormonal contraceptives don’t actually treat endometriosis

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

focus

leisure time

knowledge

hotspot